RCM
SGP

RA Capital Management’s SpyGlass Pharma SGP Stock Holding History

RA Capital Management’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179M Hold
8,021,117
– – 1.55% 15
2026
Q1 		$208M Buy
+8,021,117
New +$216M 2.2% 11

Other funds holding SGP

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

RA Capital Management's SGP Position: Q2 2026 in Review

RA Capital Management held its SpyGlass Pharma (SGP) position steady in Q2 2026 at 8,021,117 shares worth $179M. The position accounts for 1.55% of the portfolio, ranked #15.

RA Capital Management first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $208M in Q1 2026. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • RA Capital Management held 8,021,117 shares of SpyGlass Pharma worth $179M as of Q2 2026.
  • RA Capital Management left its SpyGlass Pharma share count unchanged in Q2 2026.
  • SpyGlass Pharma made up 1.55% of RA Capital Management's portfolio in Q2 2026, its #15 holding.
  • RA Capital Management first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • RA Capital Management's SpyGlass Pharma position peaked at $208M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.